BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Onsenal celecoxib regulatory update

The European Commission (EC) withdrew marketing authorization for Onsenal celecoxib from Pfizer to reduce the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP) as an adjunct to surgery and further endoscopic surveillance. The move...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >